WO2025027578A1 - Nanotechnology product formulation in liposomal form based on extra virgin olive oil, olive stem and leaf alcoholic extract and trace minerals from the gulf of california - Google Patents

Abstract

The present invention relates to a nanotechnology product formulation in liposomal form based on extra virgin olive oil, olive stem and leaf alcoholic extract and trace minerals from the Gulf of California. The formulations are highly efficient carriers for any vitamin, nutrient, drug or food supplement, ensuring the quality of the manufactured products since the invention relates to a smart drug administration system based on nano-scale particles, wherein it comprises: An oral extra virgin olive oil nanoemulsion produced from seeds with an Oleuropein content between 35% and 40% as an antioxidant agent; emulsifying agents; Gulf of California water extract; and optionally a sweetener, a flavouring and a preservative.

Description

Title of the invention: FORMULATION OF NANOTECHNOLOGICAL PRODUCTS IN LIPOSOMAL FORM BASED ON EXTRAVIRGIN OLIVE OIL, ALCOHOL EXTRACT OF THE STEM AND LEAVES OF THE OLIVE TREE AND TRACE MINERALS FROM THE SEA OF CORTES I

TECHNICAL FIELD OF THE INVENTION

[0001] The present invention relates to the field of health and nutrition, since lately technological advances have been developed in food supplements such as liposomes, which give advantage in the absorption in the body of nutritional components and / or medications, through the use of nanotechnology, that is why the present invention combines these elements in addition to being based on components of natural origin, unexpectedly solving the absorption of components such as, for example, vitamin C, since to date there is no presentation of the same that allows to assimilate doses beyond 30% of current pharmaceutical compositions, and as this technological advance for this composition is detailed below, we will be able to see that this technology is viable to be applied to other products, since the way of obtaining the liposomes of the present invention, makes them highly efficient carriers, for any other vitamin, nutrient or medication ensuring the quality of the manufactured products; since the invention corresponds to an intelligent drug administration system, based on nanoscale particles.

[0002] Nanotechnology has been defined as “concerned with materials and systems whose structures and components exhibit significantly improved physical, chemical, and biological properties, as well as phenomena and processes, due to their nanoscale size” (National Nanotechnology Initiative, 2000). [0003] Nanomedicine, the application of nanotechnology in the delivery of bioactive agents (drugs) [2], In practical terms, nanomedicine involves the development of nanoscale devices (<100 nm in diameter), referred to as “nano vectors”.

[0004] In 1995, the inventor of the present application, in his company, made the decision to begin the development of nanotechnological formulations, mainly food supplements and cosmetics. During the first 10 years, tests were carried out with different types of vegetable oils such as soy lecithin, sunflower, extra virgin olive oil and jojoba, as well as other solvents and surfactants such as SPAM and Tween 80.

[0005] After these tests, it was decided to use what is mentioned later in this same document, which constitutes the invention and which corresponds to nano liposomes not previously made and which offer enormous technical advantages, with the aim of guaranteeing greater stability, flavour and pleasant appearance for the consumer and, above all, providing the nutrients, which, with this technology, we achieve greater absorption and rapid effect on the body.

BACKGROUND OF THE INVENTION

[0006] Document US11066355B2 Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents with the patent family EP3736261A1 , EP3596041 B1 , US20200069599A1 , US10799463B2, describes liquid dosage forms for oral and parenteral administration including, but not limited to, pharmaceutically acceptable emulsions, micro emulsions, nano emulsions, solutions, suspensions, syrups and/or elixirs. In addition to the active ingredients, the liquid dosage forms may comprise inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing and emulsifying agents such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, peanut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and sorbitan fatty acid esters, and mixtures thereof. In addition to the inert diluents, the oral compositions may comprise inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing and emulsifying agents such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, peanut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and sorbitan fatty acid esters, and mixtures thereof. include additional therapeutic and/or prophylactic, additional agents such as wetting agents, emulsifying and suspending agents, sweeteners, flavorings and/or perfuming agents. In certain embodiments for parenteral administration, the compositions are mixed with solubilizing agents such as Cremophor®, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers and/or combinations thereof. This document and its family of patents refer to the use of olive oil or other types of oils, in our case the invention is that the extra virgin olive oil used is acquired from the seeds of olives processed in the month of December, because at this time the % of Oleuropein content is at its maximum, which is between 35% and 40%. Oleuropein is the main antioxidant component. In addition, this background of the state of the art refers to the use of polysorbates among others as a surfactant, but primarily for formulations for parenteral administration; in our case, our nano emulsions are oral.

[0007] In patents CN104127326A, WO2021072139A1, CN104146883A mentions the use of surfactants or emulsifiers however does not mention which ones, in our formulations Polysorbate (60 or 80) is used. In patent US20150231069A1 the use of the surfactant Tween 80 or polysorbate 80 is mentioned but the proportion used is not indicated, in our formulations it is between 7% and 10% of the formulation, for a technician with average knowledge in the field, it is not obvious to arrive at the ideal formulation from what is already known and disclosed in this background, since as detailed later in the description of the invention, there are several parameters that had to be considered to arrive at an ideal formulation.

[0008] Patents CN104127326A, WO2021072139A1 , CN104146883A mention the use of emulsifying agents, such as the liquid dosage form for oral administration includes, but is not limited to pharmaceutically acceptable lotion, micro emulsion, solution, suspension, syrup and elixir. Except active component (i.e. particle, nanoparticle, liposome, micelle, polynucleotides/lipid complex) Outside, the liquid dosage form may also contain inert diluent common in the fields, such as water or other solvents, solubilising and emulsifying. Agent, such as ethyl alcohol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-BDO, two Methylformamide, oil (especially cottonseed oil, peanut oil, corn oil, embryo oil, olive oil, castor oil and sesame oil), glycerol, Tetrahydrofurfuryl alcohol, polyethylene glycol and sorbitan fatty acid esters and their mixture. In addition to inert diluents, the orally administered composition may also include an adjuvant, such as a wetting agent, emulsifier and suspending agent, sweetener, flavouring agent and aromatic. But none of these backgrounds make any reference to polysorbate (60 or 80).

[0009] In patents US11066355B2 and its patent families (EP3736261A1, EP3596041 B1, US20200069599A1 and US10799463B2), CN104910025B, CN101990425B, US20070059248A1, CN114728886A, ethyl alcohol is mentioned as an emulsifying agent but not for the preparation of extracts.

[0010] In patent US20090252796 it mentions the use of olive leaf extract, however, in our process we use olive leaves and stems.

[0011] In patent IN264/MUM/2015 the use of seawater extracts with Calcium, Lead, Iron and Zinc is mentioned, unlike our process for trace minerals from the Sea of Cortez, the elements found are: Magnesium, Potassium, Boron, Iodine, Molybdenum, Cobalt, Zinc and 72 more minerals, which are essential minerals for the cellular functions of the body.

[0012] Patents CN104127326A and CN104146883A refer to the use of inorganic salts in a proportion of 0.02 to 1%, but are only limited to Sodium Chloride, Potassium Chloride or Calcium Chloride, our process provides more essential minerals than those indicated in said patents.

[0013] Patent KR 10-2020-0032092 mentions the use of saline solution, but does not specify the formulation. In our process, the use of trace minerals from the Sea of Cortez is defined, which is detailed later in the description of the invention.

[0014] Chinese patent application, CN113116824A describes the method of preparing a nano emulsion by means of stirring, heating, incubation and ultrasonic dispersion. In our invention, the method for obtaining the nano emulsion is through micronization, which allows the nano emulsions to remain stable for up to 18 months (studies on particle size distribution and z potential in accelerated stability studies are attached, as mentioned in the NOM-073-SSA1-2015 standard, Stability of drugs and medications, as well as herbal remedies).

[0015] Patent application US20230023038A1 establishes a method for obtaining liposomes by a pressurized mixture that uses supercritical carbon dioxide as a base. As we mentioned in our invention, the method for obtaining the nano emulsion is by means of micronization.

[0016] Patent application CN102743325A and its patent families CN102743324, CN102743326 and CN102743327, use biological methods. They also differ from our invention where the method for obtaining the nano emulsion is by means of micronization.

[0017] US patent granted US11066355B2 and its patent families (EP3736261A1, EP3596041 B1, US20200069599A1 and US10799463B2), CN104910025B, CN101990425B, US20070059248A1, CN114728886A,

IN264/MUM/2015, CN104127326A, WO2021072139A1, KR10-2020-0032092, US20090252796A1, CN104146883A, US20150231069A1, AU2018304530A1 and US10632205B2, do not mention what technology they use to obtain nano emulsions.

[0018] The Korean antecedent, KR10-2020-0032092 mentions that the emulsion was stable for a week or more, patents US11066355B2 and its patent families (EP3736261A1, EP3596041 B1, US20200069599A1 and US10799463B2), CN104910025B, CN101990425B, US20070059248A1, CN114728886A,

CN113116824A, IN264/MUM/2015, CN104127326A, CN102743325A and their patent families CN102743324, CN102743326 and CN102743327), US20230023038A1 , WO2021072139A1 , US20090252796A1 , CN104146883A, US20150231069A1 , AU2018304530A1 and US10632205B2, do not mention the time during which the nano emulsion remained stable, our invention, In contrast, it has established a maximum period of 18 months based on the results obtained in the stability tests.

[0019] In addition to all of the above, none of the patents analyzed mention stevia as a sweetener; furthermore, none of the patents analyzed mention the use of flavorings; nor is the use of potassium sorbate as a preservative mentioned.

Existing Technology

[0020] In Mexico and around the world, different technologies have been proposed to generate liposomes as we have mentioned in the background, but none of them have achieved what is achieved in our invention; since, although some of them use olive oil and generation by nano emulsion, they do so through different technologies and do not achieve what we achieved in terms of particle size (< 100 nm), z potential (positive "+"), and stability of the nano emulsions (18 months).

Technical Problem and Proposed Solution

[0021] Some of the problems of the state of the art are that drugs, vitamins and nutrients have a low bioavailability (poor absorption) _and side effects and adverse reactions, problems with food, high doses (large number of tablets) and therefore abandonment of treatment. In addition to this, for laboratories, they seek to achieve stability for longer and bioavailability of the resulting product, our invention achieves stability at 18 months including particle size < 100 nm, as indicated in this document, and which had not been achieved to date. This is achieved thanks to the method and components used that are detailed later in the description of the invention.

Description of the invention

[0022] The invention is based on the use of liposomes of extra virgin olive oil (including the stem and leaves) since the principle of the benefits of fats was considered, which among others are:

Hepatoprotectors. Bile production.

■ Fluid exchange in the lung and intestine.

■ Detox of the gastric mucosa.

■ Synthesis of lipoproteins.

■ Cognition, learning and memory.

■ Decreases adrenocorticotropic hormones (ACTH) and cortisol responses.

■ Improvement of psychiatric disorders.

■ Prevention of neurodegenerative and inflammatory events.

[0023] Where the assimilation of fats occurs as follows:

Dietary fats are emulsified by bile salts to form micelles.

Fatty acids enter the epithelial cells and form triglycerides.

Triglycerides combine with proteins within the Golgi apparatus to form Chylomicrons.

Chylomicrons enter the lacteal and are transported to the subclavian vein.

[0024] Why olive oil and olive leaf?

• High content of Polyphenolic compounds or Oleuropein (most abundant) or Hydroxytyrosol or Oleocanthal

• Synergistic action that enhances the antioxidant effect.

• Antihypertensive, antithrombotic, anti-inflammatory, hepatoprotective, anticancer and neuroprotective action.

[0025] Benefits of extra virgin olive oil

[0026] Olive oil is a functional food since apart from its high oleic acid content it contains many highly bioactive compounds. Only present in 1-2% of olive oil, it includes more than 230 compounds:

J tocopherols,

J squalene,

J fatty alcohols,

J triterpene alcohols,

J phyto-sterols,

J oleuropein,

J hydroxytyrosol and

J tyrosol

J Oleocanthal

[0027] Polyphenols and Oleic Acid

• Polyphenols, particularly hydroxytryosol and tryrosol, have been shown to have potent anti-inflammatory effects and may also influence cell proliferation, cell cycle progression, apoptosis, and arachidonic acid metabolism in cancer cells.

• Oleic acid has the ability to alter the expression of certain oncogenes (Her-2/neu) associated with aggressive breast cancer tumors. (Source: Visioli F & Bernardini E. 2011. Extra virgin olive oil polyphenols: biological activities. Curr Pharm Des 17, 786-804)

[0028] What are liposomes?

• They are microspheres.

• Oil phase + aqueous phase.

• Retains the active ingredients inside (aqueous phase).

• Retains the active ingredients on the outside (oily phase).

[0029] What are Nano-Emulsions? Nutrient/drug carriers.

• Smart management.

• Substrate that improves drug selectivity, efficacy and safety.

• Control of the release of the nutrient into the circulation.

• Improved pharmacokinetics and/or bioavailability.

[0030] Drug carriers.

The development of a technique or technology (intelligent administration) that improves the effectiveness of a group of nutrients or drugs.

[0031] LIPOSOMES (Nano Emulsions)

The trapped nutrients acquire the pharmacokinetic characteristics of the carrier.

[0032] Benefits of nano emulsions:

1. Increases bioavailability.

2. It is non-toxic.

3. Increases solubility.

4. Biocompatible.

5. Protects the active ingredients.

6. Biodegradable.

7. Non-immunogenic.

8. Minimizes side effects.

[0033] Bioavailability:

Bioavailability is understood as the percentage of a nutrient that is detected in the circulation after a certain time of having been administered, this is given by the following factors: Chemical nature.

• Pharmaceutical form (carrier).

• Metabolism of the individual.

[0034] All these elements were considered to arrive at the formulation of the invention described and claimed in this application.

[0035] The technical advantages that our invention provides are:

1. Physicochemical stability, which represents a long shelf life.

2. It is functional, which implies a therapeutic and safe effect.

3. It is reproducible on a small and large scale.

4. It is administered orally, which is practical and allows for the addition of flavor.

5. It is accessible since its costs can be low.

6. And innovative, since it is the result of an evolution in formulations and is adaptable.

[0036] As we will see in detail, the process to obtain our final product consists of several stages, which are the following, and later we will detail each of them.

A. Process for making alcoholic extract from olive leaves and stems.

B. Crystallization process of trace minerals from the Sea of Cortez.

C. Emulsification process.

Brief description of the figures

[0037] Figure 1 is a representative Finished Product (FP) HPLC Chromatogram of COENZYME Q10. Where your QUANTITATIVE ANALYSIS OF COENZYME Q10 reports:

Project Name IQK

HPLC Instrument Name-Quality

Sequence Date Acquired 2021-11-22 14:50:47-08:00

Injection Acq Method Name COENZYME QW.amx

Acq Injection Software Agilent OpenLab Acquisition Version 2.4 -

Build 2.4.0-REL 2.4.0.628

Injection Volume 20,000 μL

Signal End Time 5.999

INSTRUMENTS

Module Type Part. Serial No. Firmware Grad.

Pump Pumpo G4294B DECAH00336 B.07.26 [0001]

Sampler Samper G4294B DECAH00336 B.07.26

[0001]

Column Oven Column Compartment G4294B DECAH00336

B.07.26 [0001]

DAD Detector G4294B DECAH00336 B.07.26

[0001]

CHROMATOGRAPHIC CONDITIONS

Method of acquisition: COENZIMA QW.amx

Path: C:\CDSProjects\IQK\Results\CQENZIMAQ10\PT

ANTIOXIDANT W.sirslt

Method information

Last saved as: C:\CDSProjects\IQK\Methods\COENZYME

QW.amx Modified: 2021 -03-17 12:43:11 -07:00

Modifier: RICARDO CAZARES

Created: 2020-01-20 08:53:12-08:00

Creator: RICARDO CAZARES

Description:

Version: 2021-0317-1943-11696

DAD Method

Peak width: > 0.1 min (2 s response time) (2.5 Hz)

Slot: 4nm

UV Lamp Required: Yes

Vis Lamp Required: No

Module name: DAD

Module type G4294B

Order 1

Column furnace method

Module Display Name: Column Oven

Module type G4294B

Order 1

Grad. Pumping method

Flow rate: 1,500 mL/min

Low pressure limit: 0.00 bar

High pressure limit: 600.00 bar

Maximum flow gradient: 100,000 mL/min ² .

Primary Channel: Automatic

Module Screen Name: Pump Grad. Module type: G4294B

Order 1

Solvent composition

Sampler method

Module Display Name: Sampler

Module type G4294B

Order 1

Properties of the method

Instrument technique: Liquid chromatography

Schematic version

Schema version: 2.3

[0038] Figure 2 is an HPLC representation of Curcumin, showing 3 peaks, representing each of the curcuminoids (Bis-Demethoxy Curcumin (BDMC), Demethoxy Curcumin (DMC) and Curcumin), which provide the desired effect in the body. [0039] Figure 3 corresponds to HPLC Chromatogram of EXTRACT OF

OLIVE LEAVES AND STEMS, which represents the peak of the Oleuropein element.

QUANTITATIVE ANALYSIS OF OLEUROPEINA.

Project name IQK

HPLC Instrument Name-Quality

Sequence acquisition date 2023-05-04 12:44:12-07:00

Injection Acq Method Name OLEU.MP.amx

Injection Acq Software Agilent OpenLab Acquisition Version 2.4 - Build 2.4.0-

REL_2.4.0.628

Injection volume 20,000 μL

EndTime Signal 29.997.

INSTRUMENTS

Module Type Part. Serial No. Firmware No.

Grad. Bomb Yam G4294B DECAH00336 B.07.26 [0001]

Sampler Name G4294B DECAH00336 B.07.26 [0001]

Column Furnace Column Comparison G4294B DECAH00336 B.07.26 [0001]

DAD Detector G4294B DECAH00336 B.07.26 [0001]

CHROMATOGRAPHIC CONDITIONS

Acquisition method: OLEU.MP.amx

Path C:\CDSProjects\IQK\Results\OELUROPEINA MAYO

2023\EXTRACT.sirslt

Information about the method Last saved as: C:\CDSProjects\IQK\Methods\OLEU.MP.amx

Modified: 2023-05-03 16:34:37-07:00

Modifier: RICARDO CAZARES

Created: 2023-05-03 16:34:37-07:00

Creator: RICARDO CAZARES Description:

Version: 2023-0503-2334-37028

Properties of the Method

Instrument Technique: Liquid Chromatography

Schematic version

Schema version: 2.3

Grad. Pump method

Flow: 1,000 mL/min

Low limit pressure: 0.00 bar

High pressure limit: 600.00 bar

Maximum flow gradient: 100,000 mL/min ² .

Primary Channel: Automatic

Module Screen Name: Grad. Pump Module Type:

G4294B

Order 1

Solvent composition

Sampler method

Module Display Name: Sampler

Module type G4294B

Order 1

Column furnace method

Module Display Name: Column Oven

Module type G4294B

Order 1

DAD Method

Peak width: > 0.1 min (2 s response time) (2.5

Hz)

Slot: 4nm

UV Lamp Required: Yes

Vis lamp required: Yes

Module name: DAD

Module type G4294B

Order 1

ITUECTION RESULTS

[0040] Figure 4 Representative HPLC Chromatogram of EXTRACT OF

OLIVE LEAVES AND STEMS

QUANTITATIVE ANALYSIS OF OLEUROPEINA

Project name IQK

HPLC Instrument Name-Quality

Sequence acquisition date 2023-05-04 12:12:09-07:00

Injection Acq Method Name OLEU.MP.amx

Injection Acq Software Agilent OpenLab Acquisition Version 2.4 - Build 2.4.0-

REL_2.4.0.628

Injection volume 20,000 μL

Signal end time 29.996

INSTRUMENTS

Module Type Part. No. Serial No. Firmware Grad. Pump Pump G4294B DECAH00336 B.07.26 [0001] Sample Sample G4294B DECAH00336 B.07.26 [0001]

Column Furnace Column Compartment G4294B DECAH00336

B.07.26 [0001]

DAD Detector G4294B DECAH00336 B.07.26 [0001]

CHROMATOGRAPHIC CONDITIONS

Acquisition method: OLEU.MP.amx

Path: C:\CDSProjects\IQK\Results\OELUROPEINA MAYO

2023WITRA 1.sirslt

Information about the method Last saved as: C:\CDSProjects\IQK\Methods\OLEU.MP.amx

Modified: 2023-05-03 16:34:37-07:00

Modifier: RICARDO CAZARES

Created: 2023-05-03 16:34:37-07:00

Creator: RICARDO CAZARES

Description:

Version: 2023-0503-2334-37028

Properties of the Method

Instrumental Technique: Liquid Chromatography

Schematic version

Schema version: 2.3

Grad. Pump method

Flow: 1,000 mL/min

Low limit pressure: 0.00 bar

High pressure limit: 600.00 bar

Maximum flow gradient: 100,000 mL/min ² .

Primary Channel: Automatic

Module Screen Name: Grad. Pump

Module type G4294B

Order 1

Solvent composition

Sampler method

Module Display Name: Sampler

Module type G4294B Order 1

Column furnace method

Module Display Name: Column Oven

Module type G4294B

Order 1

DAD Method

Peak width: > 0.1 min (2 s response time) (2.5 Hz)

Slot: 4nm

UV Lamp Required: Yes

Vis lamp required: Yes

Module name: DAD

Module type G4294B

Order 1

[0041] Figure 5 Corresponds to the HPLC Chromatogram of Standard D -

Mandelonithlo

QUANTITATIVE ANALYSIS OF D-MANDELONITRILE

Project name IQK HPLC Instrument Name-Quality

Sequence acquisition date 2021-06-08 14:47:30-07:00

Injection Acq Method Name B-17.amx Injection Acq Software Agilent OpenLab Acquisition Version 2.4 - Build 2.4.0-REL_2.4.0.628

Injection volume 20,000 μL

Signal end time 5.995

INSTRUMENTS

Module Type Part. Serial No. Firmware No.

Pump Grad. Pump G4294B DECAH00336 B.07.26 [0001]

Sampler Sampler G4294B DECAH00336 B.07.26 [0001]

Column furnace Column compartment G4294B DECAH00336 B.07.26 [0001]

DAD Detector G4294B DECAH00336 B.07.26 [0001]

CHROMATOGRAPHIC CONDITIONS

Method of acquisition: B-17.amx

Path: C:\CDSProjects\IQK\Results\B-

17\PT208.06.2021 .sirslt Method information

Last saved as: C:\CDSProjects\IQK\Methods\B-17.amx

Modified: 2021-04-16 12:39:05-07:00

Modifier: RICARDO CAZARES

Created: 2021-03-09 10:17:09-08:00

Creator: RICARDO CAZARES

Description:

Version: 2021-0416-1939-05260

DAD Method

Peak width: > 0.1 min (2 s response time) (2.5

Hz)

Slot: 4nm

UV Lamp Required: Yes

Vis lamp required: Yes

Module name: DAD

Module type G4294B

Order 1

Column furnace

Method module display name: Column Homo

Module type G4294B

Order Grad. Pumping method

Flow rate: 1,100 mL/min

Low pressure limit: 0.00 bar

High pressure limit: 600.00 bar

Maximum flow gradient: 100,000 mL/min ² .

Primary Channel: Automatic

Module Screen Name: Grad. Pump

Module type G4294B

Order 1

Solvent composition

Sampler method

Module Display Name: Sampler

Module type G4294B

Order 1

Properties of the method

Instrument technique: Liquid chromatography

Schematic version

Schema version: 2.3

INJECTION RESULTS

Signal: DAD1 B, Sig=215.4 Ref=off Peak Area Width Peak Height

RT [min] plate Name Area Area ure s by % Max% Type meter (50%)

USP

D- 1695.474

1.115 11157.4267 91.4821 100,000 0.104

MANDELONITRILE MM m

284,708

1.455 1038.8743 8.5179 9.311 0.067

MB m

Sum 12196.3010

[0042] Figure 6 Corresponds to: Representative HPLC Chromatogram of Curcumin (BAS-NA LIPOSOMAL:1004-19) TR (min) 2,604 Area 980. 9348 BDMC, TR (min) 2,950 Area 1319.6872 DMC, TR (min) 3,353 Area 6829.0605; Dilution factor 20:50

QUANTITATIVE ANALYSIS OF CURCUMIN

Project name IQK

HPLC Instrument Name-Quality

Sequence Acquisition Date 2020-01-09 08:47:36-08:00

Injection Acq Method Name CURCUMINA LUIS.amx

Injection Acq Software Agilent OpenLab Acquisition Version 2.4 - Build 2.4.0- REL_2.4.0.628

Injection volume 20,000 μL

EndTime Signal 4.996 TOOLS

Module Type Part. Serial No. Firmware No.

Pump Grad. Pump G4294B DECAH00336 B.07.26 [0001]

Sampler Sampler

G4294B DECAH00336 B.07.26 [0001]

Column furnace Column compartment G4294B DECAH00336

B.07.26 [0001]

DAD Detector G4294B DECAH00336 B.07.26 [0001]

CHROMATOGRAPHIC CONDITIONS

Method of acquisition: CURCUMINA LUIS.amx

Path: C:\CDSProjects\IQK\Results\HPLC-Quality-2020-

01-09 08-47-34-08-00. rsl

Method information Last saved as: C:\CDSProjects\IQK\Methods\CURCUMINA LUIS.amx Modified: 2019-12-28 14:39:57-08:00 Modifier: RICARDO CAZARES Created: 2019-07-13 09:40:19-07:00 Creator: RICARDO CAZARES Description: CURCUMINA LUIS

Version: 2019-1228-2239-57131

DAD Method

Peak width: > 0.1 min (2 s response time) (2.5

Hz)

Slot: 4nm

UV Lamp Required: Yes

Vis Lamp Required: No

Module name: DAD

Module type G4294B

Order 1

Column furnace method

Module Display Name:

Column Furnace Module Type: G4294B

Order 1

Grad. Pumping method Flow rate: 1,500 mL/min

Low pressure limit: 0.00 bar

High pressure limit: 600.00 bar

Maximum flow gradient: 100,000 mL/min ² .

Primary Channel: Automatic

Module Screen Name: Grad. Pump

Module type G4294B

Order 1

Solvent composition

Sampler method

Display Module Name: Sampler Module Type: G4294B Order: 1

Properties of the method

Instrument technique: Liquid chromatography

Schematic version

Schema version: 2.3

INJECTION RESULTS

Signal: DAD1 B, Sig=425.4

Ref=off RT [min] Name Area Area% Max Peak% Height Type Width (50%)

1.184 28.9307 0.3130 0.423 5.544 VV

1.438 19.5400 0.2114 0.286 2.278 VV

1.629 15.2067 0.1645 0.222 1.789 VV

1.772 15.0410 0.1627 0.220 2.726 VV

1.959 22.0063 0.2381 0.322 4.036 VB

2,595 981.9250 10.6243 14,361 188,393 BB

2,941 1322.1636 14.3057 19,337 236,015 BV 3,340 6837.4003 73.9801 100,000 1110,993 VB

Sum 9242.2136

Table 1. HPLC curcumin results RT (minutes), Area and Height.

[0043] Figure 7, this refers to the analysis of olive oil reporting

And corresponding to the following table:

Sample from 6/21/2023 11:17.05 AM

[0044] Figure 8 refers to the analysis of vitamin C and states the following:

Sample ID STD SODIUM ASCORBATQ Method

Mame: C: \Usars\P ubkADocu menfetAgifendMicroLa b\Methods®STANQAR£SCAUDA£>¿2m

Sample Ssw:8 Useradmin

Background Soans:32 Qai®'Tífa®:0&19!202t W:28:33 AM

Resolution : 4 Range 4000 - &50

System Status: Good Apodizsátón:Happ-Qen«el

File Lccáfión:: C;\Users\PublVÁÜótu¡riér!teV^gi(erti\MícrcjLBb\Resijíí:s\£stBsid<sre5\ STÜ ASCOS BATO DE

SODIUM„2Q21’O849TÍ0>23GS.a2r

[0046] Las figuras 12 y 13 se refieren al análisis de tamaño de partícula del calostro liposomal, elaborado por el Instituto Tecnológico de México, con resultados de una calidad buena, reportando lo siguiente: Where said sample was analyzed on June 21, 2023. [0045] Figures 9, 10 and 11 refer to the analysis of particle size B of the complex with nanoliposomal iron, carried out by the Mexican National Technological Institute of Tijuana, where it is reported:

[0046] Figures 12 and 13 refer to the particle size analysis of liposomal colostrum, prepared by the Technological Institute of Mexico, with good quality results, reporting the following:

SAMPLE: LIPOSOMAL COLOSTRUM (KEMED/ONLY FOR).

Analysis: Hydrodynamic diameter (Dh) Sample preparation:

The sample was diluted in distilled water and measured after 24 h and 48 h. Measurement temperature: 25 °C. The analysis was performed in triplicate.

For the LIPOSOMAL COLOSTRUM sample, the Dh (% number) is 75.05 nm (99.2%) having unimodal distribution. Quality of the results: The polydispersity value of this sample is large.

(Figure 12) SAMPLE: LIPOSOMAL COLOSTRUM (KEMED/FOR ONLY). Analysis: Hydrodynamic diameter (Dh) Sample preparation: The sample was diluted in distilled water and measured after 24 h and 48 h. Measurement temperature: 25 °C. The analysis was performed in triplicate.

For the LIPOSOMAL COLOSTRUM sample, the Dh (% number) is 75.05 nm (99.2%) having unimodal distribution. Quality of the results: The value of

polydispersity of this sample is large.

Analysis: Hydrodynamic diameter (Da)

Sample preparation: The sample was diluted in distilled water and measured after 24 h and 48 h.

having uaimodal distributhm. Result ípaaliíyt The pulydispersity value of this sample is large.

Measurement temperature:25 °C. The analysis was earned out in triplicate. For the sample CALOSTRO LIPOSOMAI .. she Dh (% number) is 75.05 nto

having uaimodal distributhm. Result ípaaliíyt The pulydispersity value of this sample is large.

Sssnlt Wtedfty ; hsiSs- ^: te steW repast

In this graph we can see that it has a good result, reporting the following:

Analysis: Zeta Potential (mV)

(Figure 13) SAMPLE: LIPOSOMAL COLOSTRUM (KEMED/ONLY FOR).

Sample preparation: The sample was diluted in distilled water and measured after 24 h. Measurement temperature: 25 °C. The analysis was performed in triplicate. The analysis result shows a zeta potential of -39.9 mV (100 %).

The figure shows the unimodal distribution peak of the analyzed sample. Quality of the result: good

Analysis: Zeta Potential (mV|

SAMPLE: LIPOSOMAL COLOSTRUM (KEMEIW^LY H)«).

Sample preparation: The sample wax diluted in distilled wter and measured after 24 h..

Méásisreméni temperature: 25 ®C-

Th® analysis; was carried out in triplicate.

[0047] Las figuras 14 y 15 se refieren, al tamaño de partícula Proanselin, elaborado por el Instituto Tecnológico de Tijuana, reportando que fue elaborado bajo las siguientes condiciones, y considerando el producto con buena calidad: The result of the analysis shows up to potential of -39.9 mV (100 %). Th® figure shows unimodal dist'-ibuíioti peak of the aaaiyxed sample, Result quality: good.

[0047] Figures 14 and 15 refer to the Proanselin particle size, produced by the Tijuana Institute of Technology, reporting that it was produced under the following conditions, and considering the product to be of good quality:

The dynamic light scattering (DLS) studies for the following nano liposomal sample are reported below: PROANSELIN (PILOT BATCH) ITFOSOMA1... The. analysis carried out was hydrodynamic diameter (Ds) and zeta potential. The equipment used ts a Maiveni Instruments Nano-ZS Nanosizer (ZEN 3OÜ). The mstrumeat is equipped with a helium neon laser (633 nm) with a size detection range of 0.6 nm -5 pm. DLS experiments were performed at the scattering angle of W ^; and balanced for 2 mia before data collection.

Áiiiíüysis: íiyclmiiynsimk diameter (IM)

Sample preparation:; The sampr? or a-, PJ ₄ b\' ¡a .h'\ k<? v.jk'j .mt >v?jmred after 24 h.

Measurement tsjmperaiure: 2? \t he d\ih vs v. as; n: K d eat m u .phcnte.

For the sample PR0ANSEI JN _S the D& (% number) is 89 nm (£§. I %) having nnitnodal distributive.

Analysis: Zeta Potencial (mV) Residual quality: good.

Analysis: Zeta Potential (mV)

Sample preparation:: The sample was diluted m distilled dressing and measured after 24 fa.

Measurement temperature: 25 ^a C.

Tire imalysis was carried mt ia tri plicate.

Tire ñgiirs stews the great tolkridsl stability of the analyzed saEtiple.

The result of tire analysis stows a zeta potential

Tire ñgiirs stews the great tolkridsl stability of the analyzed saEtiple.

[0048] Figures 16 to 22 refer to an analysis carried out by the National Technological Institute of Mexico in Tijuana which reports the following:

Dynamic light scattering (DLS) studies of the following nanoliposome samples are presented below: ANTIOXIDANT 10, CURCUFLEX, VITA C PLUS, POWER PEA PROTEIN, VITA+MINS, IRON B COMPLEX, HEALTHY FISH MEAL LIPOSOMAL. The analyses performed were hydrodynamic diameter (Dh) and zeta potential. The equipment used is a Nano-ZS Nanosizer from Malvern Instruments (ZEN 3690). The instrument is equipped with a helium neon laser (633 nm) with a size detection range of 0.6 nm-5 Dm. DLS experiments were performed at a scattering angle of 90o and equilibrated for 2 minutes prior to data collection. An individual report for each sample is attached.

Figure 16 refers to SAMPLE: VITA+MINS LIPOSOMAL Aíialysis: Hydrtídyssniii' diameter (1K)

Sample preparation: The sample was diluted in distilled water and measured after 24 h.

Measutmetn temperature. 25 °C The a»alysis was mmed out in triplieafe. M) Wviag

Figure 17 corresponds to: SAMPLE: HEALTHY LIPOSOMAL FISH MEAL.

Analysis: llydr^ymunic diameter (IM

The sample was diluted in distilled water and measured after 24 h. MeasüfViiK'ht '.empsnítarS: 25 ®C, The -analy sis w» carried oúi isi triplicate. Sa.tspk pi'.'p.Jt

The sample was diluted in distilled water and measured after 24 h. MeasüfViiK'ht '.empsnítarS: 25 ®C, The -analy sis w» carried out oúi isi triplicate.

For the sample HEALTHY FISH MEAL LIPOSOMAL, the D _Si (% uante) is 130 nm (100 %) having uniform distribution. Result quality; gmxL

SU8(á.aaik W tíesríW.' Yes Bes ÍOBpt

Peats, t: 130 W.& SFS3

Peak A 0.0 ®.S 0.0

W 3: & or Bh 8»

18 corresponds to: SAMPLE: LIPOSOMAL ANTIOXIDANT 10. Analysis: Hydr&dystamic diameter (EM

Sample proparariten: The sample was diluted! m disriHed: waler and measured: after 24 k MessürsHíéíir temperature: 25 ®Q The analysis was carried out »in triplicate.

Fm-thc sample ANTfOXIOANT 10 iAPOSOMAI^ the '& (% number) is 122.4 mn (W %) ttevmg uiúutódai di&tributkm. Result quality: gm>d«

esu t t|íía y : Bte (OW te itemtem Si W (On$

esu tt|íía and :

Figure 19 corresponds to: SAMPLE: CURCUFLEX LIPOSOMAL

Analysis: Hydrodynamic diameter (Ba)

Sample preparaiter: The sample was -diluted in distilled water and measured after 24 h. Measurement temperature: 25 ®C. The analysis was carried out in triplicate.

For the siuiipls CIMCVFLEX UPOSOMAL^ the Ihs (% nambcr) is 45.71 M (99.11 %) having unisa&dal distribute». Result quality; gwt

Figure 20 corresponds to: SAMPLE: B COMPLEX WITH IRON

LIPOSOMAL

Analysis: Hydrodynamic diameter (IM

Sample preparation.- The sample was diluted in distilled water and mwamd after 24 h.

Mestetrenwi temperature; 25 ⁱ Y'. The analysis was carried out in triplicate;

Far the sample B COMPLEX WITH IRON LIPOSOMAL, site a (% uamber) is 59.13 am (W %) having unimodal distribution. Result quality: goat!» sus g&mh =% teteter.- & Bte temte

Figure 21 corresponds to: SAMPLE: VITA C PLUS LIPOSOMAL Analysis: Itydr&dynsmle ditunefer (ESfc)

Sampk pteparat-ont 1 to.- mmpk' toas dt ktivd in dt'dilk'd u a ter and n . »'i\ d ahss 24 h.

Mcgsaremersi KmpcraHjn.: 25 T' Fisa íspaksís uss earned t»ui in tnpheaie.

having tmtmodnl distab«ito.to Result quality; gwd>

For this sample VITA C FLUS LIPOSOMAL, the IA, (% number I is 45 SS UKS (9S5

having tmtmodnl distab«ito.to Result quality; gwd>

Figure 22 corresponds to: SAMPLE: POWER PEA PROTEIN

LIPOSOMAL

[0049] Figures 23 to 28 refer to another analysis carried out by the Technological Institute of Mexico Campus Tijuana, in reference to the DLS analysis of particle size, where this report presents the results carried out on our liposomal OME-NA and liposomal SEL-NA. Indicating that hydrodynamic diameter (Dh) and zeta potential analyses were carried out on the liposomal OME-NA and liposomal SEL-NA samples. The dynamic light scattering (DLS) equipment was where the measurements were made and has the following characteristics: Instruments Malvern Nano-ZS Nanosizer (ZEN 3690). The instrument is equipped with a helium-neon laser (633 nm) with a detection range of 0.6 nm -5 pm. DLS experiments were carried out with a scattering angle of 90° and equilibrated for 10 min prior to each data collection.

[0050] Figure 23 refers to the SAMPLE: LIPOSOMAL OME-NA, reporting:

Anafek: Hydrodynamic diameter (Dfe

Figure 25 corresponds to SAMPLE: OME-NA and reports: Analysis: Pderód

Team; fJLS

Preparation: The rwfcstra was diluted using distilled water.

Measuring temperature: 25 ®C.

The ;.ÍSU&Í5 was carried out by tópUcsde.

As a result of the analysis, we see a zeta of '9.59 jtnV (area 1 00%). From the figure we can observe the cofoidal stability of our analyzed material.

Figure 26 corresponds to the SEL-NA SAMPLE generating the following information:

Ariáíisis: Hydrodynamic diameter ID«)

Preparation: Nwestfa fits diluted using distilled water.

Measuring temperature. ¿S -'C.

The analysis, of redúd by tnpae.*do

As can be seen, the Dti (H in number) is 79.B8 nm>(W0 %) and the distribution is observed wmtíKÍaL Ltisge, the .LE (H in Irs tosidad) is passed d cusí is ds 22115 nía (M.é %X

Siss gUrnb b bwber; $iw lOsny s'.-AWí vyv glsss and DSS Pwk'E D ^: ss i»e 3S.43.

La figura 28 corresponde a: una MUESTRA: SEL-NA LIPOSOMAL dando los siguientes datos: Figure 27 also corresponds to the SEL-NA SAMPLE reporting:

Figure 28 corresponds to: a SAMPLE: SEL-NA LIPOSOMAL giving the following data:

Analysis; Potential zsia

Es^iEpíi: PLS

Preparation; A sample of diluted water is used.

Temperature Je i'sov ucr 25 §C

The saáUsis of principle realization>

m pvteuc'ál zeta de -34.4 a¥ (área 100 %). De la figura se pwds^: obsm^;ar la gmn tsiaNitdau c^Undai Ju la m «es ira saallzada,

From the results of ee

m pvteuc'ál zeta of -34.4 a¥ (100% area). From the figure pwds ^: obsm ^; ar la gmn tsiaNitdau c^Undai Ju la m «is saallized anger,

[0051] Figures 29 and 30 refer to SAMPLE: VITAMIN C WITH NANO LIPOSOMAL ZINC LOT NO. 509-20, made by the National Technological Institute of Mexico, Tijuana campus, which presents:

Analysis: Hydrodynamic diameter (Dh)

Sample preparation: The sample was diluted in distilled water and measured after 24 h.

Measuring temperature: 25 °C.

The analysis was performed in triplicate.

For the sample VITAMIN C WITH NANO LIPOSOMAL ZINC (LOT #509-20), the Dh (% number) is 18.29 nm (100%) having a unimodal distribution. The Dh (% intensity) is 236.3 nm (81.7%) and 27.65 nm (18.3%) showing a bimodal distribution. Quality of results: See quality report.

Figure 29

Figure 30

[0052] Figure 31 refers to:

PARTICLE SIZE of Cardio Minerals Liposomal Support, where the distribution we can observe that:

80% measures between 10 nm - 66 nm

20% measures between 122nm - 293nm

[0053] Figure 32 represents the PARTICLE SIZE of Cardio Liposomal Support which reports:

90% measures between 10 nm - 62 nm

10% measures between 126nm -139nm

[0054] Figure 33 refers to the PARTICLE SIZE of Cardio Liposomal Support which reports: 90% measures between 10 nm - 62 nm

10% measures between 126nm -139nm

[0055] Figure 34 represents the Cardio PARTICLE SIZE

Liposomal Support Minerals reporting:

80% measures between 10 nm - 66 nm

20% measures between 122nm - 293nm

From all the figures reported above we can see that these correspond to graphs that confirm the good quality of the nano liposomes of the present invention, as well as their effective use as carriers for different active substances such as vitamins, supplements or drugs, for which reason we will proceed to claim the invention once we have described the details of this.

[0056] Figures 35 to 38 are very representative because the long-term result of Proanseline A (stability) shows what was mentioned about the particle size and z potential in stability studies.

Dynamic light scattering (DLS) studies for the following nanoliposomal samples are: reported below: PROANSELIN (PROANSELIN) (long term stability and accelerated stability) LIPOSOMAL. The analysis performed was hydrodynamic diameter (Dh) and zeta potential. The equipment used is a Nano-ZS Nanosizer from Malvern Instruments (ZEN 3690). The instrument is equipped with a helium neon laser (633 nm) with a size detection range of 0.6 nm-5 pm. DLS experiments were performed at the scattering angle of 90° and equilibrated for 2 min before data collection. An individual report is attached for each sample.

These figures represent the following:

Figure 35

SAMPLE: LIPOSOMAL PROANSELIN (long-term stability)

Analysis: Hydrodynamic diameter (Dh)

esa í qsrn ty í >Sample preparation: The sample was diluted in distilled water and measured after 24 h. Measurement temperature: 25 °C. The analysis was performed in triplicate. For the PROANSELIN sample (long-term stability), the Dh (number in %) is 36.64 nm (100 %) with unimodal distribution. Result quality: good.

that í qsrn ty í >

Figure 36

Analysis: Zeta Potential (mV)

Sample preparation: The sample was diluted in distilled water and measured after 24 h. Measuring temperature: 25 °C.

The analysis was performed in triplicate. The analysis result shows a zeta potential of -41.7 mV (100%). The figure shows the high colloidal stability of the analyzed sample.

Figure 37

SAMPLE: PROANSELIN LIPOSOMAL PILOT BATCH (accelerated stability)

Analysis: Hydrodynamic diameter (Dh)

Sample preparation: The sample was diluted in distilled water and measured after 24 h. Measurement temperature: 25 °C. The analysis was performed in triplicate.

For the PROANSELIN sample (accelerated stability), the Dh (% number) is 46 nm (100%) having a unimodal distribution. Quality of the result: good

Figure 38 Analysis: Zeta Potential (mV)

Sample preparation: The sample was diluted in distilled water and measured after 24 h. Measuring temperature: 25 °C.

The analysis was performed in triplicate.

The analysis result shows a zeta potential of -46.6 mV (100%). The figure shows the high colloidal stability of the analyzed sample.

[0057] Figure 39 corresponds to the intestinal permeability test obtained by ingesting the formulation of the present invention containing iron, in which it is shown that the absorption of said trace metal is increased. That is, according to the results obtained, it is demonstrated that the amount of permeated iron compared to other pharmaceutical formulations is highly acceptable (85.39%).

Detailed Description of the Invention

[0058] The following definitions are provided for the purpose of allowing a better understanding of the invention:

[0059] “Approximately”.- The use of the term “approximately” provides a certain additional range with respect to the numerical value to which it is being applied. Said additional range is approximately ± 10%. By way of example, but not limitation, if “approximately 10 liters” is stated, the exact range that is described and/or claimed is between 9 to 11 liters. [0060] Trace minerals and their composition: Generally, between 72 and 76 trace minerals are present in the waters or salt of the Sea of Cortez. The quantity of trace minerals varies in composition and concentration depending on the time of collection, since sea evaporation is greater in summer and the contribution of minerals is greater during the rainy season, mainly due to the rainfall discharges of the Colorado River, which passes through 4 states of the American Union and empties into the port of San Felipe in the Sea of Cortez, where the Baja California peninsula begins.

[0061] Minerals make up 5% of the normal human diet, but are essential for health and optimal functioning of the body. Minerals can be classified into different groups. Macrominerals: minerals that adults need in amounts greater than 100 mg/day or that constitute < 1% of total body weight. Trace minerals or trace elements: minerals that adults require in amounts of 1 to 100 mg/day or that constitute less than 0.01% of total body weight. Ultra trace minerals: those mineral elements that are required in amounts less than 1 g/day.

[0062] Nanotechnology is the understanding and control of matter at the nanoscale, with dimensions between 1 and 100 um. It is used to create and use structures, devices and systems that have new properties and functions due to their size.

[0063] Nanos = Dwarf and Manometer = billionths of a meter

[0064] A Liposome, are nano-bubbles based on natural oils that have the ability to transport bioactive substances (vitamins, minerals, amino acids, etc.) inside or in their membrane. They have a Excellent tolerance thanks to its composition, identical to that of our cell membranes, and to the low concentration of active ingredients. They allow a controlled release of the active ingredients contained, enhancing the bioavailability of the product (release extended over time). Its particle size, less than 100 nanometres, means that they are quickly absorbed by the intestinal wall, thus considerably increasing the bioavailability of nutrients. Its structure, almost identical to the cell wall, allows for more efficient fusion and delivery and absorption up to 9 times greater than tablets or capsules with similar formulas, which increases the beneficial effect of the supplement to a higher percentage.

[0065] An intestinal permeability study is a test performed in a New York laboratory called Creative Bioarray:

[0066] By assessing the permeability of compounds in the early stages of drug discovery, compounds that are most likely to pose challenges during preclinical and clinical development can be identified. The permeability of compounds across cell membranes, such as the intestinal epithelium, is a critical characteristic that determines the rate and extent of human absorption and ultimately affects the bioavailability of a drug candidate. Compounds with poor permeability are more likely to have poor absorption, distribution, metabolism, excretion (ADME) and pharmacokinetic (PK) properties.

[0067] Nanocarriers: are capable of directing active substances to the site where they are required, with the aim of maintaining and controlling the delivery of the drug in time and space. First generation nanocarriers They comprise a passive delivery system that is located within the target site where the content is released. An example of this are nanoparticles or liposomes, which when administered with the intention of reaching a tumor as a target tissue, are forced to accumulate at the site of action due to a “promoted permeation and retention” effect or EPR. This effect occurs given the fact that tumors present fenestrations or interruptions in the cell line of the epithelia adjacent to the vascularization.

[0068] PROCESS FOR THE PRODUCTION OF ALCOHOLIC EXTRACT FROM OLIVE LEAVES AND STEMS

1. Add the crushed or powdered olive leaves and pure cane ethyl alcohol to a glass container in a ratio ranging from approximately 75:25 to approximately 25:75 respectively.

2. Shake vigorously for a period of approximately 10 minutes.

3. Allow to stand for 14 days, shaking vigorously for a period of approximately 10 minutes once a day during the standing time.

4. At the end of the resting time, filter through rapid filter paper to eliminate larger particles.

5. Pass the solution through a fiberglass filter.

6. Concentrate the volume of the solution obtained in step 5 on a rotary evaporator until it reaches approximately 20 to 30% of the initial volume. 7. Take a sample portion and analyze according to the Oleuropein analysis method, to verify that the solution obtained in step 6 contains between 30 to 35% v/v of said component.

8. If it is below the specification mentioned in step 7, proceed with the evaporation in relation to the % of the component until reaching the required 30 to 35% v/v.

9. Once the required % of Oleuropein has been reached, it is filtered through a sterile 0.45 micron filter, to achieve the sterility of the Olive Leaf and Stem Extract.

10. Store in safe containers selected from previously sanitized glass containers, identify with the name of the extract, the date of preparation and the % v/v of Oleuropein contained,

11. Use for a period of no more than 12 months, after this time, re-evaluate in HPLC.

[0069] CRYSTALLIZATION PROCESS OF TRACE MINERALS FROM THE SEA OF CORTEZ

1. Add Sea of Cortez trace minerals to a container and pour in hot purified water in a 25:75 ratio.

2. Mix with constant stirring and heating until a homogeneous solution is achieved.

3. Cool to room temperature. 4. Add pure ethyl cane alcohol and mix with constant stirring without heating. The ratio of alcohol to be added is approximately 50:50, with respect to the mineral and water mixture.

5. Let the mixture rest for 18 to 24 hours.

6. Decant the mixture, discarding the precipitate (sodium salts).

7. Heat the mixture resulting from step 6 to a temperature ranging from approximately 55°C to approximately 60°C (boiling and distillation temperature) in order to evaporate the alcohol present in the mixture.

8. Filter the aqueous solution from step 7 containing the trace minerals through a fiberglass filter.

9. Finally, filter with the help of a vacuum through a sterile 0.45 micron filter to obtain a sterile solution of trace minerals from the Sea of Cortez.

10. Take a portion of the sample and carry out the microbiological analysis.

11. Place the filtrate in a previously sanitized container.

12. Identify the name of the solution and the date of preparation.

13. Use for a period of no more than 24 months, after this time, re-evaluate through microbiological analysis and assess the concentrations of each of the trace minerals through ICP or atomic absorption.

[0070] It is understood by a technician with average knowledge in the field that steps 10 and subsequent steps correspond to a standard quality control and that they are not part of the invention, but are listed herein. request, since they are elements that demonstrate the quality that we seek to preserve and obtain in our products.

[0071 ] EMULSIFICATION PROCESS

[0072] The emulsification process of the water-soluble and fat-soluble ingredients to obtain a nanoemulsion is carried out as follows:

[0073] In the present invention, the method for obtaining the nanoemulsion is by means of micronization, which allows the nanoemulsions to remain stable for up to 18 months (studies of particle size distribution and z potential in accelerated stability studies are attached (see figures and their description, especially figures 35 to 38), as mentioned in the NOM-073-SSA1 -2015 standard, Stability of drugs and medications, as well as herbal remedies).

[0074] Our invention has established a maximum period of 18 months based on the results obtained in the stability tests.

[0075] In the present invention, the method for obtaining the nanoemulsion is by means of immersion micronization with a head, formed by a rotor and a toothed stator made of 316 L stainless steel (pharmaceutical grade), which, driven by a 3.0 horsepower (HP) explosion-proof motor, our equipment reaches up to 20,000 revolutions per minute (RPM), regulated by an Ultra Turrax type central gearbox.

[0076] This process allows nanoemulsions to remain stable for up to 18 months, obtaining a particle size between 5 nm and 100 nm, with a positive Z potential (+), a) as we mentioned, studies of particle size distribution and z potential in accelerated stability studies, as mentioned in the NOM-073-SSA1-2015 standard, Stability of drugs and medications, as well as herbal remedies, the evaluations were carried out by the National Technological Institute of Mexico, Tijuana campus.

[0077] It is understood by a technician with average knowledge in the area, that this equipment is an illustrative example of how to put the invention into practice, but that any other existing technology that achieves the same effect of obtaining nanoemulsions with these characteristics, is covered within the scope of the present invention.

[0078] The liposome preparation process consists of the following steps:

1. Dissolution phase: i. Water-soluble active ingredients: Dissolve the water-soluble ingredients in 50% of the total solvent of the formula, dividing 50% by the number of ingredients to carry out the dissolution independently. At the end, mix each of the solutions obtained, except for the dissolution of the flavorings.

i. Fat-soluble active ingredients: Dissolve the fat-soluble ingredients in 7% of the extra virgin olive oil, dissolving the ingredients one by one.

Where:

WATER-SOLUBLE ACTIVE INGREDIENTS.

- Vitamin C (Ascorbic Acid)

- Vitamin C (Sodium Ascorbate)

- Vitamin C (Calcium Ascorbate)

- Vitamin B1 (Thiamine HCL)

- Vitamin B3 (Pyrophosphate

- Vitamin B3 (Niacin/Niacinamide)

- Vitamin B6 (Pihdoxin HCL)

- Vitamin B12 (Cyanocobalamin/Hydro/Methyl cobalamin)

- Vitamin B9 (Folic Acid sodium salt)

- Vitamin B17 (Amygdalin)

- Glutathione HCL / Sodium salt

- L-Lysine HCL / Sodium Salt

- L-Arginine HCL / Sodium Salt

- Calcium (Citrate/Gluconate)

- Magnesium (Citrate/Chloride)

- Potassium (Chloride)

- Zinc (Sulfate)

- Iron (Sulfate)

- EDTA (Disodium salt)

- Amygdalin - Herbal extracts (Hydroalcoholic) examples: olive, curcumin, silymarin etc.

FAT-SOLUBLE ACTIVE INGREDIENTS

- Coenzyme Q10

- Vitamin D3

- Vitamin E

- Vitamin A

- Lipoic acid

- Omega 3

- Omega 6

- Vitamin K2

[0079] The quantities will depend on the active ingredients to be dissolved, that is, if 70% of the active ingredients in the formulation are water-soluble, it means that the formulation will have 70% water and only 7% extra virgin olive oil, otherwise, the formulation will contain 8% extra virgin olive oil and 60% purified water.

[0080] 2. Micronization process:

[0081] Introduce the aqueous solution into a container with a maximum capacity of 90% of the batch size.

[0082] Place under the micronizer and turn on the equipment for approximately 15 minutes at a speed between 15,000 and 18,000 RPM (revolutions per minute).

[0083] In a separate container with constant stirring, add the surfactant to the oily mixture, stir for a period of 5 minutes. [0084] With the micronizer on, add the oil-surfactant mixture slowly over a period of no more than 10 minutes.

[0085] 3. Microemulsion:

[0086] Micronize the aqueous-oil-surfactant mixture for a period of 15 minutes between 15,000 and 18,000 RPM.

[0087] 4. Stabilization:

[0088] With the micronizer on, add the olive stem and leaf extract slowly over a period of no more than 10 minutes. Continue with the equipment on between 15,000 and 18,000 RPM for approximately 5 minutes. Turn off the micronizer.

[0089] 5. Flavoring:

[0090] Turn on the micronizer and add the natural and artificial flavoring solution slowly over a period of no more than 10 minutes.

[0091] Obtaining the nanoemulsion:

[0092] Continue micronizing the total mixture for 5 more minutes, adding solvent to the batch size indicated in the master production order.

[0093] Take samples of the nanoemulsion for quality control to perform the following analyses:

2. Organoleptic tests: taste, color, texture, appearance. Physicochemical analysis: pH, density, microscopy, HPLC titration of ingredients, particle size and Z potential.

4. Microbiological analysis: aerobic mesophiles, fungi and yeasts, pathogens (E. Coli, Staphylococcus spp and Salmonella spp).

1. When it comes to a modification to the ingredients, change of input supplier, new formulation or new product, stability tests are used based on the NOM-073-SSA1-2015 standard, Stability of drugs and medications, as well as herbal remedies, upon complying with the time established by the standard (6 months for accelerated stability), the product is marketed.

[0094] Examples

[0095] The following are technical examples of how to carry out the invention, but it will be understood that a person skilled in the art understands that obvious variations thereon are covered within the protection of the present invention, since these are illustrative but not limiting.

[0096] Liposomal B complex

• Only 15 mg of Iron (low doses)

• Ideal for anemia

• No side effects

With olive leaf extract [0097] Using the World Health Organization (WHO) hemoglobin cut-off points, anemia is estimated to affect more than 2 billion people worldwide.

[0098] Iron deficiency anemia (IDA) remains the most common type of anemia worldwide.

[0099] In Figure 39 we can observe how permeability is obtained when ingesting the formulation of the present invention and that allows with low doses to achieve a high assimilation of Fe.

[0100] According to the Cenetec clinical guide, elemental iron is required in adults at doses of 180 mg/day divided into three doses, given that, it is related to the problems with current iron formulations, which are:

• Low bioavailability

• High doses are required

• Long treatments (up to 6 months)

• Low compliance by patients and

• Various side effects such as gastrointestinal pain, constipation, diarrhea, nausea, vomiting, heartburn, fatigue, flushing, etc.

[0101] Our formulation reduces side effects, reduces treatment time, requires a lower dose of around 30 mg, increases bioavailability, is stable for 18 to 24 months, is versatile, low cost and increases the compliance rate. This formulation is achieved with iron nanoparticles, where the particle size ranges from 5 to 75 nm, and is viable for oral administration. [0102] EDTA

[0103] It is a molecule used to detoxify heavy metal contamination in contact with humans. Its objective is to seek out minerals in the bloodstream and binds to them through four carboxylate groups and two metallic amine groups that can act as electron pair donors, or Lewis bases to form covalent bonds combined with cations that makes it a hexadentate ligand and the most important of the chelate ligands.

[0104] LINK FORMATION:

□ Mn (II)

□ Cu (II)

□ Faith (III)

□ Co (III).

[0105] This shows the Lewis structure, where the free electron pairs of oxygen and nitrogen are seen.

[0106] EDTA AS DISODIUM SALT [0107] The reagent commonly used is its disodium salt, since in practice EDTA is usually partially ionized, forming less than six coordinate covalent bonds with metal cations.

[0108]

[0109] It has 6 bonds, since it forms a hexaprotic system, giving rise to a complex with an octahedral structure.

[0110] DISODIUM EDTA Vs

[0112] EDTA DISÓDICO EDTA

[0112] DISODIUM EDTA

SOLUBILITY: 100 g/l

DENSITY: 700 g/mL

MELTING POINT: 110 °C pH: 4-5

MOLECULAR WEIGHT: 372.24 g/mol

EDTA

SOLUBILITY: 0.5 g/l

DENSITY: 700 g/mL

MELTING POINT: 220 °C (DECOMPOSITION) pH: 2.5

MOLECULAR WEIGHT: 292.24 g/mol

[0113] From the previous examples we can see the advantages of using each of our components and their practical application in each formulation, another example of application is in formulations with vitamin C.

[0114] Vitamin C has multiple health benefits, such as antioxidant, antitumor, anti-aging and helping collagen; Vitamin C can prevent, help and even cure various viral and bacterial diseases, since the action of vitamin C is dual since on the one hand it strengthens the immune system and on the other it limits the inflammatory damage, which begins when the defenses detect an infectious agent, so that the symptoms are milder, and the recovery faster, unfortunately, vitamin C has a low intestinal absorption and a rapid elimination through urine, reasons why it is a challenge to reach the doses that are required to obtain all its benefits. [0115] Its arrival to the cells is an obstacle course, since the vitamin C that we ingest in foods, supplements, capsules, gummies, solutions, effervescent tablets, lyophilized powders, etc., are absorbed in the body through specific transporters, located in the intestine, these transporters, have the capacity to introduce only a certain amount of vitamin C per minute, so only the amount of vitamin C that is capable of being transported will be absorbed, it is known that of a gram of vitamin C, only half (500mg) is absorbed, the rest is discarded; Once in the body, it has a first transformation in the liver, generating another loss when it reaches the bloodstream, it is distributed to the organs of the body, and begins its elimination process through urine, the entry of vitamin C to the cells will again depend on the quantity and functionality of the transporters located on the cell surface; It is unknown how much vitamin C reaches the cell, although it is estimated that it is less than a third of what is ingested, which is why conventional formulations do not reach the concentrations that the body requires to experience all of its benefits.

[0116] With nanotechnology, the effectiveness of vitamin C, ingested orally, can be achieved, since with this technology nano carriers can be developed for various substances such as vitamin C, and more specifically thanks to the nano liposomes of the present invention, which are obtained from vegetable fats such as olive oil, and more specifically from olive oil from the leaves and stems thereof.

[0117] Due to their size and composition, the nanoliposomes of the present invention directly penetrate the intestine, without requiring any carrier. specific, and its absorption is close to 100%; when the nano liposome measures less than 100 nm, it is not detected by the liver, passing directly into the bloodstream and organs, distributing itself throughout the body.

[0118] The surface of the nano liposomes is very similar to the cell membrane, and upon contact, it recognizes it and introduces it directly through a process called endocytosis.

This process occurs anywhere on the cell surface, without depending on any specific carrier. Once inside the cell, the nano liposome opens, releasing the administered substance. As we mentioned for the present invention, it is possible that said substance is not only vitamin C, but any other substance such as vitamins, drugs or nutrients in general. In the case of vitamin C, we can say that practically 100% of the vitamin C administered by this route is absorbed, so one gram of liposomal vitamin C will have a much greater effect compared to any other conventional form of administration. The formulation of our example with vitamin C shows that thanks to this form of administration with the formulation of the liposomes of the present invention, it is possible to reach the concentrations that are required to strengthen the immune system and maintain the protection of the individual against bacterial and viral diseases, such as influenza, flu and coronavirus, among others.

[0119] Nanoliposomes are not eliminated through urine, because they are not soluble in water, so they remain in the circulation for the necessary time to be used by the cells. [0120] In addition to this, the nano liposomes of the present invention, being made from olive oil, leaves and stems, and minerals from the Sea of Cortez, add the anti-inflammatory and antioxidant benefits of said substances.

[0121] In general, the percentages of the essential components of the formulations sought to be protected in this patent application are:

Main components per dose (15 mL):

• Extra virgin olive oil: between 7% and 8%.

• Purified water: between 60% and 70%.

• Trace minerals: between 0.50% and 1%.

• Sweetener: <0.1 %.

• Flavouring: <1 %

• Conservative: <0.1%

• Olive leaf extract: between 0.50% and 1%.

• Active ingredients: between 25% and 30%

[0122] Example 1 :

LIPOSOMAL VITAMIN C

[0123] Manufacturing process for 30 kg of new Nanoemulsion

1. Dissolve approximately 6 kg of sodium ascorbate (Vitamin C) in approximately 10 liters of purified water at room temperature and stir until completely dissolved and empty everything into the stainless steel production drum.

2. Add sodium polysorbate with gentle stirring, stir for approximately 5 minutes at 5000 rpm and stop for approximately 5 minutes.

3. Slowly add the flavor and preservative mixture with light agitation and stir for approximately 5 minutes at approximately 10,000 rpm and stop for approximately 5 minutes. 4. Add with stirring, approximately 1.5 kg. of extra virgin olive oil, stir for approximately 5 minutes at approximately 10,000 rpm and let rest for approximately 5 minutes.

5. Add approximately 180 g of citric acid dissolved in purified water and stir for approximately 5 minutes at approximately 14,000 rpm. Adjust the pH to approximately = 4.5 - 4.7

6. Weigh the total volume and top up the weight to approximately 30 kg. With purified water and shake for approximately 5 minutes at approximately 14,000 rpm and let stand for approximately 24 hours.

7. A retention sample is taken for quality control for physical, chemical and microbiological analysis; once approved by quality control, it is conditioned.

[0124] Example 2:

Preparation of liposomal proanselin:

[0125] The active ingredient called D-Mandelonithlo or Amygdalin, is a water-soluble input, as defined above, which is strictly soluble in water.

[0126] The content of amygdalin is about 1 g per about 15 mL (dose). That is, for a batch of about 30 L, about 2 kg of raw material was weighed.

[0127] For this purpose, the active ingredient was solubilized in approximately

50% of the total purified water to be used, subsequently micronized for approximately 15 min at approximately 16,000 RPM (revolutions per minute) to reach the desired particle size (less than 100 nanometers). And the processes of microemulsion, stabilization and obtaining the nanoemulsion continued.

[0128] The present disclosure has been presented for purposes of illustration and disclosure. The foregoing is not intended to limit the disclosure to the form or forms disclosed herein. In the detailed description above, for example, various features of the disclosure are grouped into one or more aspects, embodiments, and/or configurations in order to simplify the description. Features of the aspects, embodiments, and/or configurations of the disclosure may be combined into alternative embodiments and configurations other than those discussed above. The present disclosure is not to be construed as reflecting an intention that the claimed subject matter requires more features than are expressly recited in each claim.

[0129] Although the description of the invention has included one or more features, embodiments or configurations and certain variations, other embodiments, combinations and/or modifications are within the scope of the disclosure, for example, as may be within the knowledge of the person skilled in the art, after understanding the present invention.

[0130] Having sufficiently described the nature of the invention, as well as the manner of carrying it out, it must be noted that the provisions indicated above are susceptible to modifications in detail, as long as they do not alter their fundamental principle.

Claims

Claims [Claim 1] i A process for obtaining a nanotechnological formulation in liposomal form that improves the absorption of nutritional components and medications in the body, characterized in that it comprises the following steps: a. Preparation of the alcoholic extract of olive leaves and stems b. Extraction of trace minerals from the Sea of Cortez c. Emulsification of the mixture d. Preparation of liposomes [Claim 2] The process according to claim 1, characterized in that item a) comprises the following steps: a. Add crushed or pulverized olive leaves and stems and pure ethyl alcohol from cane to a container, in a ratio ranging from approximately 75:25 to approximately 25:75 respectively; b. Stir vigorously for a time interval of approximately 10 minutes; c. Allow to stand for 14 days, stirring vigorously for a time interval of approximately 10 minutes, once a day during the resting time; d. At the end of the resting time, filter through filter paper to remove larger particles and obtain a solution; e. Pass the solution through a fiberglass filter; f. Concentrate the volume of the solution obtained in step e) in a rotary evaporator until reaching approximately 20 to 30% of the initial volume; g. Take a sample portion and analyze according to the Oleuropein analysis method, to verify that the solution obtained in step f) contains between 30 to 35% v/v of said component; English: h. If the specification is below the in step g), evaporation is continued in relation to the percentage of the component until the required 30 to 35% v/v is reached; i. Once the required Oleuropein percentage is reached, filter through a sterile filter of approximately 0.45 microns to achieve sterility of the Olive Leaf and Stem Extract; j. Store in safe containers selected from previously sanitized glass containers, identify with the name of the extract, the date of preparation, and the v/v percentage of Oleuropein contained; k. Use for a period of no more than 12 months, after which time, re-evaluate on HPLC. [Claim 3] The process according to claim 1 characterized in that item b) comprises the following steps: a. Add trace minerals from the Sea of Cortez into a container and pour in hot purified water, in a ratio ranging from approximately 25:75% m/v; b. Mix with constant stirring with heating until a homogeneous solution is achieved; c. Cool to room temperature; d. Add pure ethyl alcohol from cane and mix with constant stirring without heating, the ratio of alcohol to be added is approximately 50:50% v/v, with respect to the mixture of minerals and water; e. Let the mixture rest for a range between 18 and 24 hours; f. Decant the mixture, discarding the precipitate (sodium salts); g. Heat the mixture resulting from step f to a temperature ranging from approximately 55 °C to approximately 60 °C in order to evaporate the alcohol present in the mixture; h. Filter the aqueous solution from step g containing the trace minerals through a fiberglass filter; i. Finally, filter it using a vacuum through a sterile 0.45 micron filter to obtain a sterile solution of trace minerals from the Sea of Cortez. [Claim 4] The process according to claim 3, characterized in that optionally item b) includes the steps of: a) Taking a portion of the sample and carrying out the microbiological analysis; b) Placing the filtrate in a previously sanitized container; c) Identifying with the name of the solution and the date of preparation; d) Using for a period of no more than 24 months, after this time, reevaluating through microbiological analysis and assessing the concentrations of each of the trace minerals through ICP or atomic absorption. [Claim 5] The process according to claim 1, characterized in that item c) for obtaining the nanoemulsion comprises micronization by immersion with a head, formed by a rotor and a toothed stator of 316 L stainless steel (pharmaceutical grade), which, driven by a 3.0 horsepower (HP) explosion-proof motor, the equipment reaches up to 20,000 revolutions per minute (RPM), regulated by an Ultra Turrax type central gearbox. [Claim 6] The process according to claim 5, characterized in that the process allows the nanoemulsions to remain stable for up to 18 months, obtaining a particle size between 5 nm and 100 nm, with a positive Z potential (+). [Claim 7] The process according to claim 1, characterized in that item d) consists of the following steps: a. Dissolution phase; b. Micronization process; c. Microemulsion; d. Stabilization; e. Obtaining the nanoemulsion [Claim 8] The process according to claim 7, characterized in that the dissolution phase consists of: a) Water-soluble active ingredients: Dissolve the water-soluble ingredients in 50% of the total solvent volume of the formula, dividing 50% by the number of ingredients to carry out the dissolution independently. At the end, mix each of the solutions obtained, except the dissolution of the flavorings; b) Liposoluble active ingredients: Dissolve the liposoluble ingredients in 7% volume of the extra virgin olive oil, dissolving the ingredients one by one. [Claim 9] The process according to claim 8, wherein the water-soluble active ingredients are selected from: ascorbic acid, sodium ascorbate, calcium ascorbate, thiamine HCL (vitamin B3), niacin (vitamin B3), niacinamide (vitamin B3), pyhdoxine HCL (vitamin B6), cyanocobalamin (vitamin B12), hydrocobalamin (vitamin B12), methyl cobalamin (vitamin B12), folic acid sodium salt (vitamin B9), Amygdalin (vitamin B17), glutathione HCL/sodium salt, L-lysine HCL/sodium salt, L-arginine/sodium salt, calcium citrate, calcium gluconate, magnesium citrate, magnesium chloride, potassium chloride, zinc sulfate, iron sulfate, EDTA disodium salt and herbal extracts in olive alcohol, curcumin, silimahna. [Claim 10] The process according to claim 9, wherein the fat-soluble active ingredients are selected from: coenzyme Q10, Vitamin D3, vitamin E, vitamin A, lipoic acid, Omega 3, Omega 6 or vitamin K2. [Claim 11] The process according to claim 7, characterized in that the micronization process consists of: a. Introduce the aqueous solution into a container with a maximum capacity of 90% of the batch size; b. Place under the micronizer and turn on the equipment for approximately 15 minutes at a speed between 15,000 and 18,000 RPM (revolutions per minute); c. In a separate container with constant agitation, add the surfactant to the oily mixture, stir for a period of approximately 5 minutes; d. With the micronizer on, add the oil - surfactant mixture slowly over a time not exceeding 10 minutes. [Claim 12] The process according to claim 7, characterized in that it consists of: Micronizing for a period of 15 minutes the aqueous - oil - surfactant mixture between 15,000 and 18,000 RPM. [Claim 13] The process according to claim 7, characterized in that the stabilization stage is carried out with the micronizer on, where the extract of olive stems and leaves is added slowly in a time not exceeding 10 minutes, continuing with the equipment on between 15,000 and 18,000 RPM for a time of 5 minutes, and finally the micronizer is turned off. [Claim 14] The process according to claim 7, characterized in that the emulsion is obtained by continuing with the micronization of the total mixture for approximately 5 more minutes, titrating with the solvent to the batch size indicated in the master production order. [Claim 15] The process according to claim 7, characterized in that it optionally has the following steps: a. Adding Flavouring: Turn on the micronizer and add the solution of the natural and artificial flavourings slowly in a time not exceeding 10 minutes. b. Taking samples of the nanoemulsion by quality control to perform the following analyses: a) Organoleptic tests b) Physicochemical analysis c) Microbiological analysis [Claim 16] A nanotechnological formulation in liposomal form based on extra virgin olive oil, alcoholic extract of the stem and leaves of the olive tree and trace minerals from the Sea of Cortez obtained with the process of claim 1 characterized in that it consists of: a) An oral nanoemulsion of extra virgin olive oil produced from the seeds with an Oleuropein content between 35% and 40%, as an antioxidant b) Emulsifying agents c) Extract of trace minerals from the Sea of Cortez d) Optionally a sweetener, a flavoring and a preservative [Claim 17] A nanotechnological formulation in liposomal form according to claim 16, characterized in that the method for obtaining the nanoemulsion is by means of micronization which allows the nanoemulsions to remain stable for up to 18 months. [Claim 18] A nanotechnological formulation in liposomal form according to claim 16, characterized in that the emulsifying agent is Polysorbate (60 or 80). [Claim 19] A nanotechnological formulation in liposomal form according to claim 18, characterized in that the Polysorbate (60 or 80) is between 7% and 10%. [Claim 20] A nanotechnological formulation in liposomal form according to claim 16, characterized in that the salts of the Sea of Cortez water are selected from: Magnesium, Potassium, Boron, Iodine, Molybdenum, Cobalt, Zinc and 72 other minerals. [Claim 21] A nanotechnological formulation in liposomal form according to claim 16, characterized in that stevia is used as a sweetener. [Claim 22] A nanotechnological formulation in liposomal form according to claim 16, characterized in that potassium sorbate is used as a preservative. [Claim 23] A nanotechnological formulation in liposomal form according to claims 16 to 22, characterized in that it is viable for oral administration. [Claim 24] A nanotechnological formulation in liposomal form according to claims 16 to 23, characterized in that they are highly efficient carriers for any vitamin, nutrient or medication or food supplement, i